{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:27:05Z","timestamp":1773667625678,"version":"3.50.1"},"reference-count":9,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2005,9,27]],"date-time":"2005-09-27T00:00:00Z","timestamp":1127779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetic Medicine"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dunnigan\u2010type familial partial lipodystrophy (FPLD) is caused by mutations in <jats:italic>LMNA<\/jats:italic>, the gene that encodes nuclear lamins\u00a0A and C. FPLD is characterized by peripheral fat loss, excess central adiposity, insulin resistance, and hyperlipidaemia, which are difficult to treat. We present our 2\u00a0years\u2019 experience of treatment with rosiglitazone in a subject with FPLD. Insulin requirement decreased significantly from 240\u00a0IU\/day to 76\u00a0IU\/day (range 20\u2013240\u00a0IU\/day) and serum triglyceride concentration was lowered from 13.7\u00a0\u00b1\u00a014.4\u00a0mmol\/l to 4.5\u00a0\u00b1\u00a04.3\u00a0mmol\/l and remained stable. Mean HbA<jats:sub>1c<\/jats:sub> prior to rosiglitazone therapy was 9.4\u00a0\u00b1\u00a01.32% and decreased to 7.4\u00a0\u00b1\u00a00.6% during therapy with rosiglitazone. This case demonstrates the benefits of PPAR\u03b3\u2010agonists on glycaemic control and dyslipidaemia in a patient with FPLD. This in turn implies that PPAR\u03b3 may play a pathophysiological role in FPLD.<\/jats:p>","DOI":"10.1111\/j.1464-5491.2005.01757.x","type":"journal-article","created":{"date-parts":[[2005,9,27]],"date-time":"2005-09-27T08:18:57Z","timestamp":1127809137000},"page":"1611-1613","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Long\u2010term treatment experience in a subject with Dunnigan\u2010type familial partial lipodystrophy: efficacy of rosiglitazone"],"prefix":"10.1111","volume":"22","author":[{"given":"A.","family":"L\u00fcdtke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Genschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Spuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Worman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. H.\u2010J.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,19]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"33","article-title":"Familial lipoatrophic diabetes with dominant transmission. A new syndrome","volume":"43","author":"Dunnigan MG","year":"1974","journal-title":"Quart J Med"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00430347"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.5.7500"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.11.1958"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-4-200008150-00009"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(02)00093-5"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2003.01034.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031658"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.9.2241"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-5491.2005.01757.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-5491.2005.01757.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:11:01Z","timestamp":1696939861000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-5491.2005.01757.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,19]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1464-5491.2005.01757.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01757.x","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,19]]},"assertion":[{"value":"2005-10-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}